Media Releases

2021

18/05/2021

Proteomics secures major analytical services contract

13/05/2021

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

29/04/2021

Proteomics International files US FDA 513(g) regulatory submission

23/04/2021

Proteomics International achieves ISO 13485 certification

10/02/2021

PromarkerD: Predicting Diabetic Kidney Disease Before Symptoms Arrive – Medical Forum Magazine

09/02/2021

Proteomics International (ASX:PIQ) pursues FDA approval for PromarkerD – The Market Herald

09/02/2021

Proteomics seeks FDA approval for blood test kit – The West Australian

08/02/2021

Proteomics International seeks FDA approval for PromarkerD

2020

16/12/2020

Proteomics International interviewed for Australian Government R&D Tax Incentive podcast

12/11/2020

Proteomics International Inks Israeli Distribution Deal for Diabetic Kidney Disease Immunoassay – 360Dx

12/11/2020

Proteomics inks kidney disease test deal in Mid-East – The West Australian

12/11/2020

Middle East is next market for PromarkerD immunoassay test

05/11/2020

PromarkerD clinical assay performance results published

05/11/2020

Clinical assay performance validates Proteomics kidney test – The West Australian

05/11/2020

Proteomics: ‘Studies Back PromarkerD For Kidney Disease’ – Biotech Daily

1
…
10
11
12
13
14
15
16
…
27